ANI Pharmaceuticals Inc

BSFA

Company Profile

  • Business description

    ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

  • Contact

    210 Main Street West
    BaudetteMN56623
    USA

    T: +1 218 634-3500

    E: [email protected]

    https://www.anipharmaceuticals.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    970

Stocks News & Analysis

stocks

ASX major bank drives strong quarterly profit

Profit momentum remains robust yet shares overvalued.
stocks

Ask the analyst: What to expect in earnings season?

The key metrics that matter this earnings season.
stocks

ASX healthcare share remains undervalued ahead of earnings

Margin recovery remains the key driver for this ASX healthcare share.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,040.5012.900.14%
CAC 408,372.280.000.00%
DAX 4025,099.00335.881.36%
Dow JONES (US)51,947.25235.600.46%
FTSE 10010,736.2397.060.91%
HKSE25,143.55180.320.72%
NASDAQ24,975.82161.87-0.64%
Nikkei 22564,764.01152.860.24%
NZX 50 Index13,807.3135.020.25%
S&P 5007,411.983.680.05%
S&P/ASX 2008,870.5012.600.14%
SSE Composite Index3,826.7012.500.33%

Market Movers